Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D2C7-IT + Atezolizumab in Recurrent Malignant Glioma
NCT04160494Phase 1Completed
- Sponsor
- Istari Oncology
- Start
- Feb 2020
- Primary completion
- Jun 2024
- Modality
- scFv Fragments, Immunotoxins
- Countries
- 1
01
Overview
Phase 1, open-label trial of D2C7-(scdsFv)-PE38KDEL in malignant glioma (2 arms), sponsored by Istari Oncology. Primary endpoint: Proportion of patients with an unacceptable adverse event at 2 years. Started Feb 2020; status: completed.
02
Drugs
D2C7-(scdsFv)-PE38KDEL
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT04160494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04160494.